September 22, 2025

Metastasis-Directed Radiotherapy for Oligometastatic Clear Cell Renal Cell Carcinoma

In a single-center phase II trial reported in The Lancet Oncology, Tang et al found that metastasis-directed radiotherapy without systemic therapy was associated with good outcomes in patients with ol...

The ASCO Post

September 17, 2025

Benmelstobart Plus Anlotinib vs Sunitinib as First-Line Treatment of Advanced Renal Cell Carcinoma

In an interim analysis of a Chinese phase III trial (ETER100) reported in The Lancet Oncology, Zhou et al found that the combination of the PD-L1 inhibitor benmelstobart and anlotinib improved progres...

The ASCO Post

November 22, 2023

Adjuvant Everolimus Improves Recurrence-Free Survival in Very High–Risk Renal Cell Carcinoma

A secondary analysis from the phase III SWOG S0931 EVEREST trial found that adjuvant everolimus given to patients with clear cell renal cell carcinoma at very high risk of recurrence after nephrectom...

The ASCO Post

April 21, 2021

First-Line Nivolumab Plus Cabozantinib Improves Outcomes vs Sunitinib in Advanced Renal Cell Carcinoma

The combination of nivolumab plus cabozantinib was found to be superior to the former standard, sunitinib, in the first-line treatment of advanced or metastatic renal cell carcinoma, according to the ...

The ASCO Post

January 30, 2024

Immune Checkpoint Inhibitor–Based Therapy May Have Comparative Efficacy in Black and White Patients With Metastatic Renal Cell Carcinoma

In a study presented at the 2024 ASCO Genitourinary Cancers Symposium, investigators compared the efficacy of immune checkpoint inhibitor–based therapies vs sunitinib as front-line treatment in Black ...

The ASCO Post

May 09, 2024

Belzutifan in Previously Treated Advanced Renal Cell Carcinoma

On December 14, 2023, a new treatment for unresectable locally advanced or metastatic clear cell renal cell carcinoma was approved, showing favorable outcomes compared to existing therapy.

The ASCO Post

December 27, 2023

FDA Approves Belzutifan for Advanced Renal Cell Carcinoma

On December 14, the FDA approved an HIF-2α inhibitor for patients with advanced RCC following treatment with a PD-1 or PD-L1 inhibitor and a VEGF TKI.

The ASCO Post

June 27, 2025

Can a Urine Test Minimize Postoperative Scans for RCC Recurrence?

Researchers examined whether a urine test could accurately detect clear cell renal cell carcinoma recurrence at an early stage, according to findings presented at the European Association of Urology (...

The ASCO Post

June 05, 2023

Study Sends Strong Signal Not to Sequence Immune Checkpoint Inhibitors in Advanced Kidney Cancer

Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor treatment in metastatic renal cell carcinoma: primary PFS analysis from the Phase 3, randomized, open-label CONTACT-03 study

Dana-Farber